1. Khorana AA, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. Journal of Thrombosis and Haemostasis. 2007 Mar 1;5(3):632-4.

2. Cancer-Associated Thrombosis (CAT), a neglected cause of Cancer Death: actions needed to increase health outcomes and reduce mortality. Report summarising the findings of an Expert Steering Group meeting in Belgium

3. Khorana AA, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–634.

4. Prandoni P, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.

5. Fuentes HE, et al. Cancer-associated thrombosis. Dis Mon 2016;62(5):121-58.

6. Heit JA, et al. Cancer and venous thromboembolism: Scope of the problem. Cancer Control. 2005;12(Suppl 1):5–10.

7. Lyman GH, et al. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011;117:1334-1349.

8. Mahé I, et al. The clinical course of venous thromboembolism may differ according to cancer site. The American journal of medicine. 2017 Mar 1;130(3):337-47.

9. Timp JF, et al. Epidemiology of cancer-associated venous thrombosis. Blood. 2013 Sep 5;122(10):1712-23.

10. Abdel-Razeq HN, et al. Incidental pulmonary embolism in cancer patients: clinical characteristics and outcome–a comprehensive cancer center experience. Vascular health and risk management. 2011;7:153.

11. Lyman GH, et al. Journal of Clinical Oncology. 2013 Jun 10;31(17):2189-2204.

12. Noble S, et al. Patients’ Experiences of LIving with CANcer-associated thrombosis: the PELICAN study. Patient Prefer Adherence 2015; 9: 337–345.

13. Elalamy I, et al. Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant. J Thromb haemost 2017; 15(5):848-857.

14. Brose KM, et al. Cancer-associated thrombosis: prevention and treatment. Current Oncology. 2008 Jan;15(Suppl 1):S58.

15. Levitan N, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-291.

16. Diez de los Rios de la Serna C, et al. Adherence to low molecular weight heparin treatment by patients with cancer who develop VTE. Cancer Nursing Practice. 2017;(4): 21-26.

17. Mandalà M, et al. Management of Venous Thromboembolism (VTE) in Cancer Patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 (Suppl 6): vi85-vi92.

18. (NCCN Guidelines™). Cancer-associated venous thromboembolic disease Version 1 2018.

19. Farge D, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis. 2013 Jan 1;11(1):56-70.

20. Kearon C, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149(2): 315-52.

21. Khorana AA, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902-4907

22. Lee AY, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153.

23. Lee AYY, et al. Tinzaparin vs. warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314(7):677-686.

24. Raskob GE, et al. Edoxaban for the treatment of cancer- associated venous thromboembolism. N Engl J Med. 2018; 378:615-624

25. Young AM, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018 Jul 10;36(20):2017-2023.



28. Cohen AT, et al. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. Thrombosis and Haemostasis 2017 Jan 5;117(1):57-6

29. Cancer-associated Thrombosis awareness survey. Results report summarising the findings of a Survey carry out by ECPC. October 2018.